Patents by Inventor James N. KOCHENDERFER

James N. KOCHENDERFER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN
    Publication number: 20200087667
    Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
    Type: Application
    Filed: November 14, 2019
    Publication date: March 19, 2020
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventor: James N. Kochenderfer
  • CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN
    Publication number: 20200071707
    Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
    Type: Application
    Filed: November 14, 2019
    Publication date: March 5, 2020
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventor: James N. Kochenderfer
  • CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN
    Publication number: 20200071708
    Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
    Type: Application
    Filed: November 14, 2019
    Publication date: March 5, 2020
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventor: James N. Kochenderfer
  • CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN
    Publication number: 20200071710
    Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
    Type: Application
    Filed: November 15, 2019
    Publication date: March 5, 2020
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventor: James N. Kochenderfer
  • CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN
    Publication number: 20200071709
    Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
    Type: Application
    Filed: November 15, 2019
    Publication date: March 5, 2020
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventor: James N. Kochenderfer
  • CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN
    Publication number: 20200071705
    Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
    Type: Application
    Filed: November 14, 2019
    Publication date: March 5, 2020
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventor: James N. Kochenderfer
  • CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN
    Publication number: 20200071706
    Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
    Type: Application
    Filed: November 14, 2019
    Publication date: March 5, 2020
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventor: James N. Kochenderfer
  • CHIMERIC ANTIGEN RECEPTORS TARGETING CD-19
    Publication number: 20190202913
    Abstract: The invention is directed to a chimeric antigen receptor (CAR) directed against CD19, which comprises an amino acid sequence of any one of SEQ ID NO: 1-SEQ ID NO: 13. The invention also provides T-cells expressing the CAR and methods for destroying malignant B-cells.
    Type: Application
    Filed: March 21, 2019
    Publication date: July 4, 2019
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventor: James N. Kochenderfer
  • Methods of conditioning patients for T cell therapy
    Patent number: 10322146
    Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: June 18, 2019
    Assignees: Kite Pharma, Inc., The United States of America as Represented by the Secretary, Department of Health and Human Services
    Inventors: Adrian Bot, Jeffrey S. Wiezorek, William Go, Rajul Jain, James N. Kochenderfer, Steven A. Rosenberg
  • Chimeric antigen receptors targeting CD-19
    Patent number: 10287350
    Abstract: The invention is directed to a chimeric antigen receptor (CAR) directed against CD19, which comprises an amino acid sequence of any one of SEQ ID NO: 1-SEQ ID NO: 13. The invention also provides T-cells expressing the CAR and methods for destroying malignant B-cells.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: May 14, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventor: James N. Kochenderfer
  • ANTI-CD30 CHIMERIC ANTIGEN RECEPTORS
    Publication number: 20190062426
    Abstract: Chimeric antigen receptors (CARs) that specifically bind to and immunologically recognize CD30 are disclosed. Related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs are also disclosed. Methods of treating or preventing a condition in a mammal, wherein the condition is cancer, are also disclosed.
    Type: Application
    Filed: October 10, 2016
    Publication date: February 28, 2019
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Service
    Inventor: James N. Kochenderfer
  • METHODS OF CONDITIONING PATIENTS FOR T CELL THERAPY
    Publication number: 20180369283
    Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.
    Type: Application
    Filed: April 10, 2018
    Publication date: December 27, 2018
    Applicants: Kite Pharma, Inc., United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Adrian BOT, Jeffrey S. WIEZOREK, William GO, Rajul JAIN, James N. KOCHENDERFER, Steven A. ROSENBERG
  • DIAGNOSTIC METHODS FOR T CELL THERAPY
    Publication number: 20180344767
    Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes methods of identifying a patient who would respond well to a T cell therapy or conditioning a patient prior to a T cell therapy so that the patient responds well to a T cell therapy. The conditioning involves administering one or more preconditioning agents prior to a T cell therapy and identifying biomarker cytokines prior to administering a T cell therapy.
    Type: Application
    Filed: May 27, 2016
    Publication date: December 6, 2018
    Applicants: Kite Pharma, Inc., The United States of America as represented by the Secretary Department of Health and Human Services
    Inventors: Adrian BOT, Jeffrey S. WIEZOREK, William GO, Rajul JAIN, James N. KOCHENDERFER, Steven A. ROSENBERG
  • CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN
    Publication number: 20180051292
    Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
    Type: Application
    Filed: August 31, 2017
    Publication date: February 22, 2018
    Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventor: James N. Kochenderfer
  • Methods of conditioning patients for T cell therapy
    Patent number: 9855298
    Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: January 2, 2018
    Assignees: Kite Pharma, Inc., The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Adrian Bot, Jeffrey S. Wiezorek, William Go, Rajul Jain, James N. Kochenderfer, Steven A. Rosenberg
  • METHODS OF CONDITIONING PATIENTS FOR T CELL THERAPY
    Publication number: 20170368101
    Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.
    Type: Application
    Filed: July 13, 2017
    Publication date: December 28, 2017
    Applicants: Kite Pharma, Inc., United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Adrian BOT, Jeffrey S. WIEZOREK, William GO, Rajul JAIN, James N. KOCHENDERFER, Steven A. ROSENBERG
  • CHIMERIC ANTIGEN RECEPTORS TARGETING CD-19
    Publication number: 20170107286
    Abstract: The invention is directed to a chimeric antigen receptor (CAR) directed against CD19, which comprises an amino acid sequence of any one of SEQ ID NO: 1-SEQ ID NO: 13. The invention also provides T-cells expressing the CAR and methods for destroying malignant B-cells.
    Type: Application
    Filed: June 1, 2015
    Publication date: April 20, 2017
    Applicants: Department of Health and Human Services
    Inventor: James N. Kochenderfer
  • Methods of Conditioning Patients for T Cell Therapy
    Publication number: 20160346326
    Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.
    Type: Application
    Filed: May 27, 2016
    Publication date: December 1, 2016
    Applicants: Kite Pharma, Inc., National Cancer Institute
    Inventors: Adrian BOT, Jeffrey S. WIEZOREK, William GO, Rajul JAIN, James N. KOCHENDERFER, Steven A. ROSENBERG